TNFSF13B and hyperthyroxinemia: Serum BAFF concentrations have been noted to be increased in autoimmune disease [39] Animal studies with BAFF and APRIL inhibitors have shown a reduction in hyperthyroxinemia and TSH receptor antibodies in a murine model of Grave's disease [40].